Journal of Pediatric Gastroenterology and Nutrition · 2007 · 510 citations · 6 references
MedicineOncologyPharmacotherapyGastrointestinal OncologyImmunopharmacologyImmunotherapyImmune-related Adverse EventsImmunosuppressionImmunosuppressive AgentsImmunosuppressive TherapyImmunotherapy SafetyInflammatory Bowel DiseaseAdverse Effects Of ImmunosuppressionAdverse Event Regulatory ReportingAdverse Event Reporting RatesInflammatory Bowel Disease ImmunopathogenesisInflammatory Bowel Disease PathologyInflammatory Bowel Disease TherapyRare Childhood CancersTumor Necrosis Factor Therapy
Hepatosplenic T cell lymphoma (HSTCL) are rare cancers ( approximately 100 published cases worldwide) and comprise 5% of peripheral T cell lymphomas. As of October 5, 2006, the FDA's Adverse Event Reporting System has received 8 cases of HSTCL in young patients using infliximab, a tumor necrosis factor-alpha blocking agent, to treat inflammatory bowel disease (6 of the 8 cases had a fatal outcome). All 8 patients were receiving concomitant immunosuppressant therapy (eg, azathioprine, prednisone). It has not been established that infliximab had an exclusive or primary role in the pathogenesis of these HSTCL cases; however, it appears that patients using this product may be at greater risk for developing this rare lymphoma.
6